15
Participants
Start Date
January 31, 2008
Primary Completion Date
September 30, 2010
Study Completion Date
June 30, 2012
Doxil
1 cycle: 3 weeks; 30 mg/m\^2, IV, every cycle
Bevacizumab (Avastin)
1 cycle: every 3 weeks; 15 mg/kg, IV, beginning on cycle 2 and every cycle 20-24 hours following Doxil administration
Bellevue Hospital, New York
NYU Cancer Center, New York
NYU medical center (Tisch Hospital), New York
Univ. of New Mexico cancer research and treatment center, Albuquerque
Collaborators (1)
Genentech, Inc.
INDUSTRY
University of New Mexico Cancer Center
OTHER
NYU Langone Health
OTHER